Joseph S, et al. - Through an analysis in a large contemporary cohort of 832 boys with Duchenne muscular dystrophy in the United Kingdom, researchers assessed the fracture burden and growth impairment relative to glucocorticoid (GC) regimen. A high fracture burden was documented in the large group of boys with DMD; incidence of fracture was a minimum four times that seen in healthy boys. The highest fracture incidence rate and the greatest degree of linear growth failure was associated with daily treatment deflazacort. Clinical trials of primary bone protective therapies and strategies to improve growth in boys with DMD are urgently suggested, but stratification based on GC regimen could be needed.